“Then as Bobby just talked about, you know, we see that pacing to the closer to the midpoint in 2026. And getting there in 2027.”

In context

“ss model toward a more expansive view of the healthcare markets. That is less fragmented and more integrated to better serve consumers and the overall system. And the components of that should allow us to continue to grow at strong levels we've experienced in the past. And that's our outlook on it. And, Josh, just maybe a little bit on margin. Maybe Tim has a comment. He made some comments on Medicare particular with the IRA changes. And, Tim, maybe if you just could reflect on those. Tim Noel: Good morning, Jeff. Thank you. So, you know, we talked about the reframing of the fraud-based Medicare Advantage targeted margin range really kind of really not all that different, just the mechanical implications of more revenue coming through the IRA without, necessarily any incremental earnings. Then as Bobby just talked about, you know, we see that pacing to the closer to the midpoint in 2026. And getting there in 2027. On the commercial business, 2026 will be a year where we'll not get all the way into our target margin range seven to nine percent, but certainly see a path to get there thereafter. So really no change bottom line. To the targeted margin range across UHC. John Rex: John, any more? I think just maybe Tim's comment that he made on call in terms of how he thinks about Medicare Advantage with the addition of those IRA dollars and such. Doesn't change really the productivity of the business. It's just that that piece of the revenue impacts the margin count calculation that came in piece of revenue that came in without really any earnings attached. To it to when it came in. So similar profile. And in general, I don't think we were actually ever seeing the full portfolio of Opta perform to its f”